![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, February 02, 2020 6:55:58 AM
Moreover, I've NEVER understood how several of the execs can own such a comparatively small portion of the OS (at least in their names), just check the filings--I own more than several of the principals--while Tim owns hundreds of millions, now into billions of shares: what specifically is the dynamic at play here? Is Tim essentially Daddy Warbucks and calls the shots period? Are the scientists--without whom this "business" is even more worthless than it has become under Tim--hostage to his vision and voice (either figuratively or literally)?
If the NM docs got suckered in like the rest of us, I can't imagine that they are happy or will take any of this lying down. Then again, how could they rationally and realistically invest to such an extent professionally without knowing Tim's business plan, IN DETAIL, for increasing market cap (the only meaningful measure of shareholder value) organically, aggressively, and steadily?
Furthermore, who but the stupidest dropout from project management school would engage in such public actions as touting the arrival of "marketing gurus" like Mells (and the blonde-haired lady who was apparently Dr. Gershman's social media wizard--I forget her name)--all of which suggests readiness to launch in a high-profile, public way--without having FIRST built the DEMAND to support such statements (and staff roles)? Where is the contingent thinking? Where is the keen awareness of game theory and REAL strategic thinking and planning? Where is the project manager who functions as a cunning and capable AWAC entity, scanning the terrain and continually reconciling the detailed strategy with the operational execution at extremely minute and compressed intervals?
Finally (for now), for as far back as I can recall, they have spoken of "commercializing" their patents rather than selling them. With that in mind, and in the context of public announcements about Mells, the "contract with Russia," etc., many invested much on the supposition that $CELZ-- having risen from the .002 range to where it was when I discovered it around .015 (when folks like Gershman and Said were posting on social media about CaverStem's effectiveness)--was on the early leg of an organic "lift-off." That was obviously NOWHERE near realistically supported by what was going on "behind the curtain."
So back to commercialization: from the moment they created a self-standing entity (CaverStem International--over which Gershman presides) I imagined that they might eventually sell that segment of the business. If THAT is what they mean(t) by "commercialization," I suppose that is an acceptable functional application of that word (as opposed to setting up the business and managing it going forward: it's clear that they do not have the ability to do that in anything even approaching a smooth and reasonably logical and predictable way).
Recent CELZ News
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/05/2024 08:05:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:02:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:45:39 PM
- Creative Medical Technology Holdings Provides Corporate Update • Business Wire • 03/27/2024 01:00:00 PM
- Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access • Business Wire • 03/07/2024 02:15:00 PM
- Biotech Finds Mid-Week Success Following FDA Announcement • AllPennyStocks.com • 03/06/2024 09:10:00 PM
- Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy • Business Wire • 03/06/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 09:05:37 PM
- Creative Medical Technology Holdings Provides Corporate Update • PR Newswire (US) • 11/15/2023 01:00:00 PM
- Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain • PR Newswire (US) • 10/10/2023 12:00:00 PM
- Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain • PR Newswire (US) • 09/19/2023 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2023 08:45:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/29/2023 09:37:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/28/2023 01:00:18 PM
- Creative Medical Technology Holdings Regains Compliance With Nasdaq Listing Requirements • PR Newswire (US) • 06/28/2023 12:00:00 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM